Strategic Collaborations Momentum Daisy Genomics has announced multiple strategic partnerships with Oak Ridge National Laboratory, University of Tennessee, ETHIA, New Day Diagnostics, and Health IT Now, signaling a collaboration led growth model and openness to co development, licensing, and joint research—ideal entry points for business development to pursue license deals, sponsored projects, or pilot programs with pharma, diagnostics, and CROs.

Oncology Focus Ready The company is pursuing next generation epigenetic sequencing and liquid biopsy tools for early colorectal cancer detection, indicating a strong oncology play with potential buyers among cancer centers, diagnostic developers, and liquid biopsy firms; target these segments with pilot studies, research collaborations, and service based arrangements.

Early Stage Advantage With a small team and modest funding, Daisy Genomics may prioritize strategic partnerships over large scale direct sales, creating opportunities for partners to co fund development or licensing in exchange for early access, exclusivity, or milestone based agreements.

Lab to Market Value The proprietary optical sequencing approach aims to streamline workflows by removing library preparation and enabling faster genomic analysis, a compelling value prop for labs and CROs seeking faster turnaround; explore research contracts, pilot services, and distribution or licensing arrangements.

Data and Ecosystem Needs As Daisy scales, there will be growing needs for data management, cloud analytics, and system integration; sales opportunities exist for cloud and software partners, bioinformatics services, and instrumentation integration to support end to end workflows.